Venture Partners, L.P. Javelin Net Worth

The estimated Net Worth of Venture Partners, L.P. Javelin is at least $7.84 Milion dollars as of 24 June 2015. Venture Javelin owns over 800,000 units of Ritter Pharmaceuticals stock worth over $7,840,000 and over the last 9 years Venture sold RTTR stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Javelin RTTR stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Ritter Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently Venture bought 800,000 units of RTTR stock worth $4,000,000 on 24 June 2015.

The largest trade Venture's ever made was buying 800,000 units of Ritter Pharmaceuticals stock on 24 June 2015 worth over $4,000,000. On average, Venture trades about 266,667 units every 0 days since 2015. As of 24 June 2015 Venture still owns at least 800,000 units of Ritter Pharmaceuticals stock.

You can see the complete history of Venture Javelin stock trades at the bottom of the page.

What's Venture Javelin's mailing address?

Venture's mailing address filed with the SEC is ONE RINCON CENTER, 101 SPEAR STREET, SUITE 255, SAN FRANCISCO, CA, 94105.

Insiders trading at Ritter Pharmaceuticals

Over the last 9 years, insiders at Ritter Pharmaceuticals have traded over $124,250 worth of Ritter Pharmaceuticals stock and bought 1,819,751 units worth $8,518,572 . The most active insiders traders include Noah Doyle, Venture Partners, L.P. Javelin oraz Matthew W Foehr. On average, Ritter Pharmaceuticals executives and independent directors trade stock every 86 days with the average trade being worth of $1,400,057. The most recent stock trade was executed by Noah Doyle on 12 March 2020, trading 500,000 units of RTTR stock currently worth $110,000.

What does Ritter Pharmaceuticals do?

Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.

Complete history of Venture Javelin stock trades at Ritter Pharmaceuticals

Ritter Pharmaceuticals executives and stock owners

Ritter Pharmaceuticals executives and other stock owners filed with the SEC include:

• Ira Ritter,
  Director
• Amy Broidrick,
  Independent Director
• Kurt Kruger,
  Independent Director
• Matthew Korenberg,
  Independent Director
• Richard David,
  Independent Director
• Shishir Sinha,
  Vice President - Operations
• Wajdi Abdul-Ahad,
  Chief Scientific Officer, Vice President - Research & Development
• Christopher Lotz,
  Chief Financial Officer, Vice President - Finance
• Michael Poirier,
  Chairman of the Board, President, Chief Executive Officer
• Paul V Maier,
  Director
• Michael D Step,
  CEO
• William M. Merino,
  Director
• Ellen F. Mochizuki,
  VP, Finance
• Partners Llc Stonehenge,
  10% owner
• Matthew W Foehr,
  Director
• Gerald T Proehl,
  Director
• Venture Partners, L.P. Javelin,
  10% owner
• Andrew J Ritter,
  CEO and President
• Noah Doyle,
  Director
• Jeffrey S Benjamin,
  VP of Finance
• John W Beck,
  Chief Financial Officer
• Venture Partners I Spv I, L...,
  10% owner